S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Global vaccines project to revamp rules after Britain got more than Botswana

* COVAX assigned early Pfizer shots to vaccination leaders UK, UAE * Dose-sharing methodology doesn't check states' vaccine coverage * Vaccine alliance Gavi is proposing changes - internal document * UK was among few countries that had Pfizer freezers, Gavi says * Gavi began to spend $25 million on cold-chain freezers in August By Francesco Guarasc
A
P
S

Financial Times - Aug. 4

Aug 4 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - UK weighs national security concerns over Nvidia's $40bn move for Arm Link - Sweaty Betty sold for $410 million as pandemic propels 'athleisure' further Link - Credit Suisse to face 't
C
N
S

S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delta worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * Dupont, Discovery slide despite strong earnings * Translate Bio surges on sale to Sanofi in $3.2-bln deal * Focus on services sector data, jobs report this week * Indexes up: Dow 0.8%, S&P 0.82%, Nasdaq 0.55% By Echo Wang NEW YORK, Aug 3
A
D
F
N
S
T
U
U

S&P closes at record high as Apple, healthcare stocks help shrug off Delta worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) By Echo Wang NEW YORK, Aug 3 (Reuters) - Wall Street's main indexes closed higher on Tuesday on gains in Apple and healthcare stocks, despite concerns over a surge in the Delta variant of the coronavirus taking some shine off an upbeat corp
A
D
F
N
S
U
U

Apple, healthcare stocks help Wall St shrug off Delta worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * Dupont, Discovery slide despite strong earnings * Translate Bio surges on sale to Sanofi in $3.2-bln deal * Focus on services sector data, jobs report this week * Indexes up: Dow 0.63%, S&P 0.63%, Nasdaq 0.29% By Echo Wang Aug 3 (Reuters)
A
D
F
N
S
T
U
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.